Elias J Jabbour1, Nicola Gökbuget2, Hagop M Kantarjian1, Xavier Thomas3, Richard A Larson4, Sung-Soo Yoon5, Armin Ghobadi6, Max S Topp7, Qui Tran8, Janet L Franklin8, Stephen J Forman9, Anthony S Stein9. 1. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2. Department of Medicine, Goethe University Hospital, Frankfurt, Germany. 3. Department of Hematology, Lyon-Sud Hospital, Pierre-Benite, France. 4. Department of Hematology and Oncology, University of Chicago, Chicago, Illinois. 5. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. 6. Division of Hematology and Oncology, Department of Medicine, Washington University School of Medicine, St Louis, Missouri. 7. Department of Haematology, Wurzburg University, Wurzburg, Germany. 8. Amgen Inc, Thousand Oaks, California. 9. Gehr Family Center for Leukemia Research, City of Hope, Duarte, California.
Abstract
BACKGROUND: Blinatumomab, a bispecific T-cell-engaging (BiTE®) immuno-oncology therapy, demonstrated superior overall survival versus standard-of-care chemotherapy (SOC) in adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (R/R ALL) in the phase 3 TOWER study. Herein, the authors reported clinical features and outcomes for those patients who underwent allogeneic hematopoietic stem cell transplantation (HSCT) after treatment with blinatumomab. METHODS: In the TOWER study, adults with R/R ALL were randomized 2:1 to receive blinatumomab or SOC. Study treatment consisted of 2 cycles of induction with blinatumomab or SOC followed by consolidation and maintenance therapy. At any time after the first cycle, patients who were eligible for HSCT could proceed to HSCT. RESULTS: Of the 97 patients who underwent HSCT during the study, baseline characteristics generally were comparable and donor types were similar between the patients treated with blinatumomab (65 patients) and those receiving SOC (32 patients). There was no evidence to suggest that the survival benefit of HSCT differed between the patients treated with blinatumomab and those receiving SOC (P = .68). On the basis of descriptive statistics, a survival benefit of HSCT versus no HSCT was not observed in patients who achieved complete remission with full, partial, or incomplete hematologic recovery with blinatumomab (odds ratio, 1.17; 95% CI, 0.54-2.53). The best outcomes were achieved in patients with no prior salvage therapy and with minimal residual disease response to blinatumomab regardless of on-study HSCT status. CONCLUSIONS: Survival was found to be driven by response to study treatment and by salvage status regardless of on-study HSCT status. These data should be interpreted with caution because the current study was not designed to prospectively assess survival outcomes associated with HSCT after blinatumomab. LAY SUMMARY: Evidence before this study: Blinatumomab is associated with superior morphologic and molecular response rates and superior overall outcome when compared with standard of care chemotherapy in adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Added value of this study: The best outcomes with blinatumomab were observed in patients who achieved minimal residual disease remission in first salvage treatment regardless of subsequent allogeneic stem cell transplantation (HSCT). Implications of all the available evidence: Patients achieving CR/CRh/CRi following blinatumomab can have a durable response with or without HSCT.
BACKGROUND: Blinatumomab, a bispecific T-cell-engaging (BiTE®) immuno-oncology therapy, demonstrated superior overall survival versus standard-of-care chemotherapy (SOC) in adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (R/R ALL) in the phase 3 TOWER study. Herein, the authors reported clinical features and outcomes for those patients who underwent allogeneic hematopoietic stem cell transplantation (HSCT) after treatment with blinatumomab. METHODS: In the TOWER study, adults with R/R ALL were randomized 2:1 to receive blinatumomab or SOC. Study treatment consisted of 2 cycles of induction with blinatumomab or SOC followed by consolidation and maintenance therapy. At any time after the first cycle, patients who were eligible for HSCT could proceed to HSCT. RESULTS: Of the 97 patients who underwent HSCT during the study, baseline characteristics generally were comparable and donor types were similar between the patients treated with blinatumomab (65 patients) and those receiving SOC (32 patients). There was no evidence to suggest that the survival benefit of HSCT differed between the patients treated with blinatumomab and those receiving SOC (P = .68). On the basis of descriptive statistics, a survival benefit of HSCT versus no HSCT was not observed in patients who achieved complete remission with full, partial, or incomplete hematologic recovery with blinatumomab (odds ratio, 1.17; 95% CI, 0.54-2.53). The best outcomes were achieved in patients with no prior salvage therapy and with minimal residual disease response to blinatumomab regardless of on-study HSCT status. CONCLUSIONS: Survival was found to be driven by response to study treatment and by salvage status regardless of on-study HSCT status. These data should be interpreted with caution because the current study was not designed to prospectively assess survival outcomes associated with HSCT after blinatumomab. LAY SUMMARY: Evidence before this study: Blinatumomab is associated with superior morphologic and molecular response rates and superior overall outcome when compared with standard of care chemotherapy in adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Added value of this study: The best outcomes with blinatumomab were observed in patients who achieved minimal residual disease remission in first salvage treatment regardless of subsequent allogeneic stem cell transplantation (HSCT). Implications of all the available evidence: Patients achieving CR/CRh/CRi following blinatumomab can have a durable response with or without HSCT.
Authors: Mary-Elizabeth M Percival; Ryan C Lynch; Anna B Halpern; Mazyar Shadman; Ryan D Cassaday; Chaitra Ujjani; Andrei Shustov; Yolanda D Tseng; Catherine Liu; Steven Pergam; Edward N Libby; Bart L Scott; Stephen D Smith; Damian J Green; Ajay K Gopal; Andrew J Cowan Journal: JCO Oncol Pract Date: 2020-05-05
Authors: Amandeep Salhotra; Dongyun Yang; Sally Mokhtari; Monzr M Al Malki; Haris Ali; Karamjeet S Sandhu; Ahmed Aribi; Samer Khaled; Matthew Mei; Elizabeth Budde; David Snyder; Thai Cao; Ricardo Spielberger; Guido Marcucci; Vinod Pullarkat; Stephen J Forman; Ryotaro Nakamura; Anthony Stein; Ibrahim Aldoss Journal: Biol Blood Marrow Transplant Date: 2020-02-05 Impact factor: 5.609
Authors: Max S Topp; Nicola Gökbuget; Gerhard Zugmaier; Anthony S Stein; Hervé Dombret; Yuqi Chen; Josep-Maria Ribera; Ralf C Bargou; Heinz-August Horst; Hagop M Kantarjian Journal: Cancer Date: 2020-11-03 Impact factor: 6.860
Authors: Giuliana Beneduce; Antonia De Matteo; Pio Stellato; Anna M Testi; Nicoletta Bertorello; Antonella Colombini; Maria C Putti; Carmelo Rizzari; Simone Cesaro; Monica Cellini; Elena Barisone; Fara Petruzziello; Giuseppe Menna; Rosanna Parasole Journal: Cancers (Basel) Date: 2022-01-15 Impact factor: 6.639